

JOINT WORKING EXECUTIVE SUMMARY

Project Title: Somerset Cancer Programme

Project Description

The aim of this joint working project is to drive a step change in cancer outcomes across Somerset, and make better use of resources allocated to cancer patients. This programme will encompass patients across the Somerset CCG geography, building on pilots for targeted tumours and cohorts where the Symphony model is more developed initially before spreading out county-wide at maturity. It will build on the strong foundations already established across the area through the Symphony programme, e.g. the uniquely insightful data infrastructure for the region, and new models of enhanced primary care.

This programme will lay the foundations for a world-class cancer model for Somerset - defining the vision, key components and processes to consistently deliver the right care to the right people at the right time. The programme aims to catalyse material improvements in clinical outcomes and patient experience, and in doing so reduce the total cost of care for cancer patients in Somerset.

Organisations Involved

Roche Products Ltd and NHS England South West Strategic Clinical Network, coordinating contributions from Yeovil FT, NHS England South (South West), Taunton and Somerset FT, Somerset CCG

Somerset Cancer Programme and Vision

The Somerset Cancer Programme will work with leading local clinicians and healthcare professionals to drive targeted, transformative improvements in cancer care delivery and outcomes for the people of Somerset.

This programme will be established by the Strategic Clinical Network for the South West, and generate momentum and progress that will support the emerging Cancer Alliance covering Somerset. Findings, initiatives and outcomes developed through this programme are envisioned to feed into the Alliances, with a view to being spread across the South West. The programme is also a key workstream within the Somerset Sustainability and Transformation plan (STP).

International evidence suggests that world-class cancer care is made up of a series of building blocks that define the clinical, operational and financial models across every touch point in cancer care delivery, from early diagnosis to end of life care. World leaders in cancer care are organised to deliver some, if not all, of these components to enhance clinical outcomes and patient experience, and in the process reducing unnecessary spend and total cost of care. The ambition is to develop a comparably ambitious cancer care model in Somerset, using this programme as a catalyst.

Benefits to Patients:

An improved understanding by all stakeholders in the system responsible of patient care of the current outcomes they are achieving for patients and a clear plan of what can be improved and how
As a result of the above, we would anticipate that patients will receive better-coordinated care, access to more innovative interventions and as a result improved outcomes.

Benefit to NHS:

Provide clarity on how care is currently being delivered and patient outcomes.
Provide the NHS with a feedback of service provision and opportunity to identify improvement areas.

JOINT WORKING EXECUTIVE SUMMARY

Benefits to Roche:

An improved understanding of the entire patient pathway in cancer, including upstream and downstream impacts of intervention on patient outcomes. An improved understanding of how cancer will be commissioned and redesigned in future. The potential creation of financial headroom to support the uptake of appropriate innovative interventions, a key part of world-class cancer care.

Roche Products Ltd contribution to Joint Working Project £86,000 (made up of prorated Roche staff time equivalent and professional management consulting expertise provided through Oliver Wyman Ltd, NHS prorated staff contribution of £81,000 coordinated through the South West Strategic Clinical Network but made up of contributions from Yeovil FT, NHS England South West, Taunton and Somerset FT, Somerset CCG towards a total budget of £167,250.